Dr Lea Hachmeister

Dr Lea Hachmeister is a life sciences lawyer specialising in regulatory advice in the European healthcare market and on digitalisation projects. She advises pharmaceutical and medical technology companies, providers of digital health solutions and investors on regulatory issues such as clinical research, market entry and reimbursement pathways for drugs and medical devices, telemedicine, strategic collaborations, and industry-specific data protection and compliance issues. Ms Hachmeister has particular expertise in cross-border projects and transactions in the healthcare sector.

IP & Copyright Law
Data Protection Law
Commercial & Distribution Law, Product Liability/Product Compliance

Dr. Lea Hachmeister studied law at Philipps University in Marburg, where she also obtained an additional qualification in pharmaceutical law. After passing her first state examination, she wrote a dissertation on the topic of ‘Clinical trials with adults incapable of giving consent – Legal framework for research for the benefit of a group.’

Dr. Hachmeister worked in an international commercial law firm in the life sciences and healthcare sector before joining Luther in July 2025.

• Best Lawyers 2026: Recommendation ‘Ones to Watch’ in the category ‘Health Law’
• The Legal 500 Germany: Recommendation in the category ‘Industry Focus - Health’ (2024).

• [Lifespin GmbH] - Advice on establishing a research collaboration in the field of AI-supported precision medicine with Acibadem University and the Acibadem Healthcare Group.
• [Myonex Inc.], a leading global provider of clinical trial supply solutions - Advice on the acquisition of the trial sample and pharmaceutical wholesale business from Hubertus Apotheke am Salzufer.
• [NORD Holding] - Advice on the acquisition of HSK health solutions GmbH, a contract manufacturer of dietary supplements and pharmaceuticals.
• [SubjectWell] - Advised on the acquisition of Trials24, which provides digital solutions for patient recruitment for clinical trials.
• [Oakley Capital] - Advised on the acquisition of Flemming Dental, Excent and the Artinorway Group.
• [AUCTUS Capital Partners AG] - Advised on the sale of the PharmaLex Group.
• [Dentsply Sirona] - Advised on digitalisation projects.

• Support Association for the Research Centre for Pharmaceutical Law
• Editorial Advisory Board of the journal PharmR
• German Legal Society for Animal Welfare Law
• Amnesty International

• 10.07.2025: KI-Verordnung & Datenschutz - Spannungsverhältnis oder Synergiepotentiale? I Ausschuss Digitale Zukunft des Bundesverbandes der pharmazeutischen Industrie.
• 26.11.2024: The EU AI Act´s impact on Pharma - Webinar
• 14.03.2024: Die Dezentralisierung klinischer Studien im Spannungsfeld zu Good Clinical Practice und Gesundheitsdatenschutz; 27. Marburger Gespräche zum Pharmarecht